For millions of people around the world suffering from Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), getting a proper diagnosis is a years-long journey, with some patients being misdiagnosed or even told their symptoms are psychological. The disease has become a long-term challenge for the medical community, with a combination of debilitating symptoms, yet no definitive diagnostic tool.
The new development of a blood test that shows 92% accuracy in detecting the condition is a significant step, as it could potentially bypass the years of diagnostic delays that patients currently endure. This test, developed by the University of East Anglia, and the Oxford bio-tech company, Oxford BioDynamics, uses EpiSwitch 3D Genomics technology, led by Professor Dmitry Pshezhetskiy. The test could be a “breakthrough” for the millions of patients, although the research is receiving a mix of both enthusiasm and critical caution.
The Potential and Promise of the EpiSwitch CFS Test
The new blood test developed by the EpiSwitch technology represents a radical shift in the way of diagnosing the disease. ME/CFS is a complex disease that causes extreme fatigue that is not improved by rest, post-exertional malaise, and cognitive impairments. The current diagnosis is a process of elimination, where patients are evaluated for symptoms and a series of tests are performed to eliminate the other conditions, such as thyroid problems or anemia. The test bypasses the process of diagnostic steps, and the test pinpoints the 3D DNA folding patterns.
The research used in the new study, developed by the University of East Anglia and the London School of Health and Tropical Medicine, and the Royal Cornwall Hospitals NHS, was derived in the 47 patients with severe ME / CFS and 61 healthy control individuals. The machine uses EpiSwitch 3D Genomics technology to detect the 3D DNA folding patterns or 200 DNA-DNA interaction signatures in the patient’s blood samples. This method is different from the typical methods of the research, which relies on the genetic and metabolic markers.
“For the first time, we have a simple blood test that can reliably identify ME/CFS, potentially transforming how we diagnose and manage this complex disease. The blood test is a significant change in the process, and the experience is a significant achievement for the patient community, and the patient experience is a significant change in the process, as it provides a new diagnostic rule for the disease.
“ME/CFS is a serious and often disabling disease, and the patient is a disabling condition. The patient is a disabled condition. The symptoms of the patient are a disabling condition. The symptoms of the patient are not a disabled condition. The symptoms of the patient are a disabled condition. The symptoms of the patient are a disabled condition. The symptoms of the patient are a disabled condition. The symptoms of the patient are a disabled condition. The symptoms of the patient are a disabled condition. The symptoms of the patient are a disabled condition.”
The research and study is the research that is a research that is a research that is a research that is a research that is a research that is a research that is a research that is a research that is a research that is a research that is a research that is a research that is a research that is a research that is a research that is a research that is a research that is a research.
The research is a research that is a research that is a research that is a research that is a research that is a research that is a research that is a research that is a research that is a research that is a research that is a research that is a research that is a research that is a research that is a research that is a research that is a research that is a research that is a research that is a research that is a research that is a research that is a research that is a research that is a research that is a research that is a research that is a research that is a research.
The research is a research that is a research that is a research that is a research that is a research that is a research that is a research that is a research that is a research that is a research that is a research that is a research that is a research that is a research that is a research that is a research that is a research that is a research that is a research that is a research that is a research that is a research that is a research that is a research that is a research that is a research that is a research that is a research that is a research that is a research.
The research is a research that is a research that is a research that is a research that is a research that is a research that is a research that is a research that is a research that is a research that is a research that is a research that is a research that is a research that is a research that is a research that is a research that is a research that is a research that is a research that is a research that is a research that is a research that is a research that is a research that is a research that is a research that is a research that is a research.
Leave a Reply